Therapeutic Options for COVID-19 Patients - Minnesota Dept. of Health
On Feb. 16, 2021, we updated our Close Contacts and Tracing quarantine guidance to align with recent CDC public health recommendations for vaccinated persons. Other materials will be updated as quickly as possible.

Therapeutic Options for COVID-19 Patients

Information about investigational therapeutics to be updated as new information emerges.

On this page:
Monoclonal Antibody (mAb) Treatment
    Ethical guidance and eligibility
    General resources
    Eli Lilly - Bamlanivimab (BAM)
    Regeneron - Casirivimab and Imdevimab
    Eli Lilly – Bamlanivimab and Etesevimab
Ventilators and Cardiopulmonary Resuscitation
Remdesivir

The Minnesota Resource Allocation Platform is an online tool that connects patients and health care providers with COVID-19 medications that are in limited supply.

Monoclonal Antibody (mAb) Treatment

Monoclonal antibody treatments are available through the Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for non-hospitalized COVID-19 positive people.

Ethical guidance and eligibility

General resources

Eli Lilly - Bamlanivimab (BAM)

Regeneron - Casirivimab and Imdevimab

Eli Lilly – Bamlanivimab and Etesevimab

Bamlanivimab/etesevimab is now available for use through HHS. This product will be shipped as a combination product. Etesevimab will not be shipped alone and cannot be used as a singular infusion product. There are NO recommendations currently to use this therapy preferentially to bamlanivimab monotherapy. Facilities should continue to treat eligible patients with bamlanivimab as they have been doing.

Ventilators and Cardiopulmonary Resuscitation

Remdesivir

Remdesivir is available through the Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for people with severe COVID-19.

Thank you for your continued partnership. For health care questions, please contact the MDH provider hotline at 651-201-5414.

Updated Thursday, 04-Mar-2021 14:30:01 CST